• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Adlai Nortye Ltd.

    8/8/24 6:02:40 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANL alert in real time by email
    6-K 1 tm2419981d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    under the Securities Exchange Act of 1934

     

    For the month of August 2024

     

    Commission File Number: 001-41773

     

    Adlai Nortye Ltd.

     

    c/o PO Box 309, Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    x Form 20-F                ¨ Form 40-F

     

     

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit No. Description
       
    99.1 Press Release: Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress and Announces Appointment of New Director

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Adlai Nortye Ltd.
       
      By : /s/ Yang Lu
      Name : Yang Lu
      Title : Chief Executive Officer and Chairman of Board of Directors

     

    Date: August 8, 2024

     

     

     

     

    Get the next $ANL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANL

    DatePrice TargetRatingAnalyst
    6/2/2025Buy → Neutral
    H.C. Wainwright
    9/4/2024$9.00Buy
    H.C. Wainwright
    10/24/2023$30.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ANL
    Leadership Updates

    Live Leadership Updates

    See more
    • Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors

      SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a global clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Mr. Roger Sawhney, M.D. to its Board of Directors as a director, effective August 8, 2024. Dr. Sawhney has nearly 30 years of financial and strategic expertise spanning the biopharma industry. "Dr. Sawhney brings a wealth of financial experience from both the pharmaceutical corporate sector and healthcare investment perspectives," said Carsten Lu, CEO and Chairman of Adlai Nortye. "Our team welcom

      8/8/24 8:00:00 AM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

      SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024. Dr. Tse, M.D. & Ph.D. earned Doctor of Medicine and Doctor of Biochemistry and Molecular Biology degrees from the University of Southern California. Prior to joining Adlai Nortye, Dr. Tse served as the Chief Scientific Officer, Senior Vice President, Head of Resear

      3/29/24 6:00:00 AM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Adlai Nortye Ltd.

      SC 13G - Adlai Nortye Ltd. (0001944552) (Subject)

      3/4/24 4:02:34 PM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANL
    SEC Filings

    See more
    • SEC Form 6-K filed by Adlai Nortye Ltd.

      6-K - Adlai Nortye Ltd. (0001944552) (Filer)

      5/30/25 8:00:01 AM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 20-F/A filed by Adlai Nortye Ltd.

      20-F/A - Adlai Nortye Ltd. (0001944552) (Filer)

      5/9/25 7:58:51 PM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Adlai Nortye Ltd.

      20-F - Adlai Nortye Ltd. (0001944552) (Filer)

      4/30/25 4:01:34 PM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025

      SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, April 10, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago. Adlai Nortye has two abstracts scheduled for presentations at AACR. "We are pleased to present the progress of our innovative pipeline at the upcoming 2025 AACR Annual Meeting. We are especially proud of our R&D capabilities in designing and developing our multi-specific immune-oncology platf

      4/10/25 8:00:00 AM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors

      SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a global clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Mr. Roger Sawhney, M.D. to its Board of Directors as a director, effective August 8, 2024. Dr. Sawhney has nearly 30 years of financial and strategic expertise spanning the biopharma industry. "Dr. Sawhney brings a wealth of financial experience from both the pharmaceutical corporate sector and healthcare investment perspectives," said Carsten Lu, CEO and Chairman of Adlai Nortye. "Our team welcom

      8/8/24 8:00:00 AM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

      SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024. AN0025 is a selective EP4 inhibitor that demonstrates antitumor activity by modulating the function of macrop

      5/23/24 9:03:04 PM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Adlai Nortye Ltd. downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Adlai Nortye Ltd. from Buy to Neutral

      6/2/25 11:24:27 AM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Adlai Nortye Ltd. with a new price target

      H.C. Wainwright initiated coverage of Adlai Nortye Ltd. with a rating of Buy and set a new price target of $9.00

      9/4/24 7:16:56 AM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Adlai Nortye Ltd. with a new price target

      Cantor Fitzgerald initiated coverage of Adlai Nortye Ltd. with a rating of Overweight and set a new price target of $30.00

      10/24/23 6:10:09 AM ET
      $ANL
      Biotechnology: Pharmaceutical Preparations
      Health Care